• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Amicus Therapeutics Inc.

    11/14/24 11:37:23 AM ET
    $FOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $FOLD alert in real time by email
    SC 13G 1 tm2428293d19_sc13g.htm SC 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G*

    (Rule 13d-102)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO § 240.13d-2

    (Amendment No. )*

     

     

    Amicus Therapeutics, Inc.
    (Name of Issuer)
     
    Common Stock
    (Title of Class of Securities)
     
    03152W109
    (CUSIP Number)
     
    September 30, 2024
    (Date of Event Which Requires Filing of the Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x Rule 13d-1(b)
    o Rule 13d-1(c)
    o Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

    CUSIP: 03152W109 Page 2

     

     

    1.

     

    NAME OF REPORTING PERSONS

     

    William Blair Investment Management, LLC

     

    2.

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (see instructions)

    (a)     o

    (b)     o

     

     

    3.

     

    SEC USE ONLY

     

     

    4.

     

     

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH

     

    5.

     

    SOLE VOTING POWER

     

    14,002,505

     

    6.

     

    SHARED VOTING POWER

     

    0

     

    7.

     

    SOLE DISPOSITIVE POWER

     

    15,582,962

     

    8.

     

     

    SHARED DISPOSITIVE POWER

     

    0

     

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    15,582,962

     

    10.

     

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    (SEE INSTRUCTIONS)

    o

     

    11.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    5.3%

     

    12.

     

     

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    IA

           

    3

     

     

     

    CUSIP: 03152W109 Page 3

     

    Item 1(a). Name of Issuer:
      Amicus Therapeutics, Inc.
    Item 1(b). Address of Issuer’s Principal Executive Offices:
      47 Hulfish Street, Princeton, New Jersey, 08542
       
    Item 2(a). Name of Person Filing:
      William Blair Investment Management, LLC
    Item 2(b). Address of Principal Business Office or, if none, Residence:
      150 North Riverside Plaza, Chicago, IL 60606
    Item 2(c). Citizenship:
      Delaware
    Item 2(d). Title of Class of Securities:
      Common Stock
    Item 2(e). CUSIP Number:
      03152W109
    Item 3. If this statement is filed pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:
      (a) o Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);
      (b) o Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
      (c) o Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
      (d) o Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
      (e) x An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
      (f) o An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
      (g) o A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
      (h) o A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
      (i) o A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);
      (j) o A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);
      (k) o Group, in accordance with § 240.13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____________.

     

     

     

     

    CUSIP: 03152W109 Page 4

     

    Item 4. Ownership:
      Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
      (a) Amount beneficially owned: 15,582,962
      (b) Percent of class: 5.3%
      (c) Number of shares as to which the person has:
        (i) Sole power to vote or to direct the vote: 14,002,505
        (ii) Shared power to vote or to direct the vote: 0
        (iii) Sole power to dispose or to direct the disposition of: 15,582,962
        (iv) Shared power to dispose or to direct the disposition of: 0
    Item 5. Ownership of Five Percent or Less of a Class:
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following. o
    Item 6. Ownership of More Than Five Percent on Behalf of Another Person:
      N/A
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company:
      N/A
    Item 8. Identification and Classification of Members of the Group:
      N/A
    Item 9. Notice of Dissolution of Group:
      N/A
    Item 10. Certifications:
      By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

     

    CUSIP: 03152W109 Page 5

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      Date:  November 14, 2024
         
      By:  /s/ Stephanie Braming
         
      Name:  Stephanie Braming
         
      Title:  Partner, Global Head of Investment Management
         

     

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative’s authority to sign on behalf of such person shall be filed with the statement, Provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

     

    Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations

    (see 18 U.S.C. 1001).

     

     

     

     

     

    Get the next $FOLD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $FOLD

    DatePrice TargetRatingAnalyst
    12/17/2025$17.00Buy
    Citigroup
    9/18/2025$14.00Hold → Buy
    Needham
    7/17/2025$108.00Equal-Weight → Overweight
    Morgan Stanley
    12/13/2024$17.00 → $12.00Overweight → Equal-Weight
    Morgan Stanley
    9/6/2024$18.00Buy
    Jefferies
    5/30/2024$18.00Overweight
    Wells Fargo
    5/14/2024$13.00Neutral → Buy
    Guggenheim
    12/19/2023$15.00 → $20.00Equal-Weight → Overweight
    Morgan Stanley
    More analyst ratings

    $FOLD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    From Super Fibers to Super Deals: Science, Scale, and Strategic Capital Shape the Morning Tape

    DENVER, Dec. 19, 2025 (GLOBE NEWSWIRE) -- This morning's market narrative spans futuristic materials, transformational biotech M&A, and creative capital restructuring, underscoring how innovation-driven companies are pairing long-term vision with near-term execution. Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB): Spider Silk Moves From Legend to Industrial Reality Kraig Biocraft Laboratories set a distinctive tone with a detailed Christmas shareholder letter that framed 2025 as the company's inflection year, marking its transition from prolonged development into early commercialization of recombinant spider silk. The operational message was concrete, as Kraig Labs highlighted major adv

    12/19/25 9:48:44 AM ET
    $FOLD
    $PBM
    $PRPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases, Accelerating Revenue Growth and Strengthening Financial Outlook

    BioMarin to Gain Galafold® (migalastat) for Fabry Disease and Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) for Pompe Disease, Adding Two Marketed, High-Growth Products with $599 Million in Revenue Over Past Four Quarters Provides Opportunity to Expand Access to Galafold and Pombiliti + Opfolda to Patients in New Markets Across BioMarin's Global Footprint; Pending U.S. Galafold Patent Litigation Resolved Will Accelerate Revenue Growth Immediately After Close; Expected to be Accretive to Non-GAAP Diluted Earnings Per Share (EPS) in the First 12 Months Post-Close and Substantially Accretive to Non-GAAP Diluted EPS Beginning in 2027 Conference Call Today at 8:15 a.m. Eastern Tim

    12/19/25 7:45:00 AM ET
    $BMRN
    $FOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Breakthrough Therapies Advance as Rare Disease Burden Intensifies Across Aging Populations

    AUSTIN, Texas, Dec. 04, 2025 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Chronic illnesses and rare disorders among older Americans represent a rapidly intensifying challenge for the U.S. healthcare system, with the National Institutes of Health estimating that more than 30 million people nationwide are living with a rare disease. Most of these conditions have no FDA-approved therapies, leaving older adults particularly at risk as age-related changes can mask or delay accurate diagnosis. This growing strain on care has heightened the need for novel treatments that address significant unmet medical needs. Soligenix Inc. (NASDAQ:SNGX) (Profile), a late-stage biopharmaceutical develope

    12/4/25 8:30:00 AM ET
    $AMGN
    $CTOR
    $FOLD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $FOLD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Citigroup initiated coverage on Amicus Therapeutics with a new price target

    Citigroup initiated coverage of Amicus Therapeutics with a rating of Buy and set a new price target of $17.00

    12/17/25 9:12:12 AM ET
    $FOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amicus Therapeutics upgraded by Needham with a new price target

    Needham upgraded Amicus Therapeutics from Hold to Buy and set a new price target of $14.00

    9/18/25 8:32:28 AM ET
    $FOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amicus Therapeutics upgraded by Morgan Stanley with a new price target

    Morgan Stanley upgraded Amicus Therapeutics from Equal-Weight to Overweight and set a new price target of $108.00

    7/17/25 7:51:00 AM ET
    $FOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FOLD
    SEC Filings

    View All

    SEC Form DEFA14A filed by Amicus Therapeutics Inc.

    DEFA14A - AMICUS THERAPEUTICS, INC. (0001178879) (Filer)

    12/19/25 9:26:26 AM ET
    $FOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amicus Therapeutics Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure

    8-K - AMICUS THERAPEUTICS, INC. (0001178879) (Filer)

    12/19/25 9:24:53 AM ET
    $FOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Amicus Therapeutics Inc.

    SCHEDULE 13G/A - AMICUS THERAPEUTICS, INC. (0001178879) (Subject)

    12/3/25 11:13:29 AM ET
    $FOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FOLD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Campbell Bradley L exercised 70,426 shares at a strike of $9.03 and sold $846,011 worth of shares (77,926 units at $10.86), decreasing direct ownership by 0.66% to 1,129,782 units (SEC Form 4)

    4 - AMICUS THERAPEUTICS, INC. (0001178879) (Issuer)

    12/17/25 6:21:26 PM ET
    $FOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief People Officer Clark David Michael sold $282,073 worth of shares (25,643 units at $11.00), decreasing direct ownership by 9% to 271,332 units (SEC Form 4)

    4 - AMICUS THERAPEUTICS, INC. (0001178879) (Issuer)

    12/17/25 6:19:31 PM ET
    $FOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Campbell Bradley L exercised 14,587 shares at a strike of $9.03 and sold $146,011 worth of shares (14,587 units at $10.01) (SEC Form 4)

    4 - AMICUS THERAPEUTICS, INC. (0001178879) (Issuer)

    12/3/25 8:11:29 PM ET
    $FOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FOLD
    Financials

    Live finance-specific insights

    View All

    From Super Fibers to Super Deals: Science, Scale, and Strategic Capital Shape the Morning Tape

    DENVER, Dec. 19, 2025 (GLOBE NEWSWIRE) -- This morning's market narrative spans futuristic materials, transformational biotech M&A, and creative capital restructuring, underscoring how innovation-driven companies are pairing long-term vision with near-term execution. Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB): Spider Silk Moves From Legend to Industrial Reality Kraig Biocraft Laboratories set a distinctive tone with a detailed Christmas shareholder letter that framed 2025 as the company's inflection year, marking its transition from prolonged development into early commercialization of recombinant spider silk. The operational message was concrete, as Kraig Labs highlighted major adv

    12/19/25 9:48:44 AM ET
    $FOLD
    $PBM
    $PRPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases, Accelerating Revenue Growth and Strengthening Financial Outlook

    BioMarin to Gain Galafold® (migalastat) for Fabry Disease and Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) for Pompe Disease, Adding Two Marketed, High-Growth Products with $599 Million in Revenue Over Past Four Quarters Provides Opportunity to Expand Access to Galafold and Pombiliti + Opfolda to Patients in New Markets Across BioMarin's Global Footprint; Pending U.S. Galafold Patent Litigation Resolved Will Accelerate Revenue Growth Immediately After Close; Expected to be Accretive to Non-GAAP Diluted Earnings Per Share (EPS) in the First 12 Months Post-Close and Substantially Accretive to Non-GAAP Diluted EPS Beginning in 2027 Conference Call Today at 8:15 a.m. Eastern Tim

    12/19/25 7:45:00 AM ET
    $BMRN
    $FOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amicus Therapeutics Announces Third Quarter 2025 Financial Results and Corporate Updates

    Q3 2025 Total Revenue of $169M, up 17% at CER Positive Q3 2025 GAAP Net Income of $17M Cash Position of $264M, a $33M Increase in Q3 2025 Conference Call and Webcast Today at 8:30 a.m. ET PRINCETON, N.J., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today announced financial results for the quarter ended September 30, 2025. "Amicus achieved yet another impressive quarter, delivering revenue growth of 17 percent and reaching the milestone of GAAP profitability. We served more patients than ever before, driven by new Galafold starts and gr

    11/4/25 7:00:00 AM ET
    $FOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FOLD
    Leadership Updates

    Live Leadership Updates

    View All

    Amicus Therapeutics Appoints Simon Harford as Chief Financial Officer

    Daphne Quimi to Retire At Year End PHILADELPHIA, Aug. 21, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today announced that Simon Harford has been appointed Chief Financial Officer, effective immediately. Simon brings extensive financial leadership experience, having served in significant finance roles in two global pharmaceutical companies as well as most recently as a public company CFO in the biotechnology industry. Daphne Quimi has decided to retire and will remain an Amicus employee through the end of the year to ensure a smooth transition. "Th

    8/21/23 7:00:00 AM ET
    $FOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amicus Therapeutics Appoints Eiry W. Roberts, M.D. to its Board of Directors

    PHILADELPHIA, June 14, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD), today announced the election and appointment of Eiry W. Roberts, M.D. to its Board of Directors. Dr. Roberts is an esteemed drug developer who brings approximately 30 years of pharmaceutical industry experience to the Company's Board of Directors, having served in various leadership positions throughout her career and bringing extensive experience advancing therapies across all phases of drug development. John F. Crowley, Chairman and Chief Executive Officer of Amicus Therapeutics, Inc., stated, "On behalf of our Board of Directors, I am pleased to announce the appointment of Dr. Eiry Roberts to the Amicus

    6/14/21 7:00:00 AM ET
    $FOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amicus Therapeutics Appoints Sébastien Martel as Senior Vice President of Strategy and Business Development

    Most Recently Served as Global Head of Rare Diseases at Sanofi Genzyme Brings Deep Expertise in Corporate Strategy, Business Development and Commercialization PHILADELPHIA, May 06, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD) today announced the appointment of Sébastien Martel as Senior Vice President of Strategy and Business Development. Mr. Martel will lead the Company's corporate strategy and business and corporate development endeavors. He will be a member of the Amicus senior leadership team. Mr. Martel brings 25 years of diversified pharmaceutical and biotechnology expertise to Amicus, with extensive experience in rare disease, most recently as Senior Vice President

    5/6/21 7:00:00 AM ET
    $FOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FOLD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Amicus Therapeutics Inc.

    SC 13G/A - AMICUS THERAPEUTICS, INC. (0001178879) (Subject)

    11/14/24 9:00:58 PM ET
    $FOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Amicus Therapeutics Inc.

    SC 13G - AMICUS THERAPEUTICS, INC. (0001178879) (Subject)

    11/14/24 11:37:23 AM ET
    $FOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Amicus Therapeutics Inc.

    SC 13G/A - AMICUS THERAPEUTICS, INC. (0001178879) (Subject)

    11/14/24 9:31:54 AM ET
    $FOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care